Morgan Stanley Maintains Overweight on Western Midstream, Raises Price Target to $35

Morgan Stanley analyst Robert Kad maintains Western Midstream (NYSE:WES) with a Overweight and raises the price target from $31 to $35.

byBenzinga Newsdesk

July 20, 2022

1 minute read

Morgan Stanley analyst Robert Kad maintains Western Midstream (NYSE:WES) with a Overweight and raises the price target from $31 to $35.

Morgan Stanley Maintains Overweight on Five9, Lowers Price Target to $160

By Benzinga Newsdesk

Today, 10:18 AM

Morgan Stanley analyst Meta Marshall maintains Five9 (NASDAQ:FIVN) with a Overweight and lowers the price target from $180 to $160.

FIVN

40 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 10:18 AM

Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million stock repurchase program.

ACY

Processa Pharmaceuticals In-Licenses Ocuphire’s Anticancer Agent

By Vandana Singh

Today, 10:18 AM

Processa Pharmaceuticals Inc (NASDAQ:PCSA) has entered into a licensing agreement with Ocuphire Pharma Inc (NASDAQ:OCUP) to in-license RX-3117. RX-3117 is an oral anticancer…

OCUP

Bitcoin Bottom Is In, Apex Crypto Is Heading To ‘$220,000+ This Cycle,’ Says Max Keiser

By Murtuza Merchant

Today, 10:18 AM

Trader, podcaster, and Bitcoin (CRYPTO: BTC) evangelist Max Keiser says that the world’s largest digital currency has bottomed out in this cycle and is well on its way to crossing the $220,000 price point.

$ADA

Morgan Stanley Maintains Overweight on Western Midstream, Raises Price Target to $35

Related Posts

Morgan Stanley Maintains Overweight on Five9, Lowers Price Target to $160

40 Stocks Moving In Monday’s Mid-Day Session

Processa Pharmaceuticals In-Licenses Ocuphire’s Anticancer Agent

Bitcoin Bottom Is In, Apex Crypto Is Heading To ‘$220,000+ This Cycle,’ Says Max Keiser